Regulatory perspective | Current status and the post-COVID outlook for antibiotic clinical trials & approvals

Moderator:

• John Rex, Chief Medical Officer, F2G Ltd.

Speakers:

• Sumathi Nambiar – Director Division of Anti-Infective Products, Office of Infectious Diseases, FDA
• Marco Cavalieri – Head of Antiinfectives and Vaccines, Safety&Efficacy Sector, EMA